Table of Contents Table of Contents 2 List of Tables 6 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) Overview 8 Therapeutics Development 9 Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) - Products under Development by Stage of Development 9 Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) - Products under Development by Therapy Area 10 Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) - Products under Development by Indication 11 Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) - Pipeline Products Glance 13 Late Stage Products 13 Early Stage Products 14 Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) - Products under Development by Companies 15 Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) - Products under Development by Universities/Institutes 18 Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) - Therapeutics Assessment 20 Assessment by Monotherapy/Combination Products 20 Assessment by Mechanism of Action 21 Assessment by Route of Administration 23 Assessment by Molecule Type 25 Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) - Companies Involved in Therapeutics Development 27 BioMAS Ltd. 27 Biotest AG 28 enGene, Inc 29 Intrexon Corporation 30 LEO Pharma A/S 31 Merck & Co., Inc. 32 P2D Bioscience 33 Pfizer Inc. 34 SK Biopharmaceuticals Co., Ltd. 35 Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) - Drug Profiles 36 AM-0010 - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 ANV-103 - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 AS-101 - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 Biologic to Activate Glutamic Acid Decarboxylase and IL-10 for Type 1 Diabetes - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 Biologic to Target Gluten and IL-10 for Celiac Disease - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 Biologic to Target Insulin Receptor and IL-10 for Type 1 Diabetes - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 BT-063 - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 Cell Therapy to Activate IL-10 for Autoimmune Myocarditis and Inflammation - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 Dekavil - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 EG-10 - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 EG-12 - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 Elmyelin - Drug Profile 50 Product Description 50 Mechanism Of Action 50 R&D Progress 50 Gene Therapy to Activate Interleukin 10 for Atherosclerosis - Drug Profile 51 Product Description 51 Mechanism Of Action 51 R&D Progress 51 Gene Therapy to Activate Interleukin-10 for ALS - Drug Profile 52 Product Description 52 Mechanism Of Action 52 R&D Progress 52 LEO-32731 - Drug Profile 53 Product Description 53 Mechanism Of Action 53 R&D Progress 53 MK-1966 - Drug Profile 54 Product Description 54 Mechanism Of Action 54 R&D Progress 54 PD-2244 - Drug Profile 55 Product Description 55 Mechanism Of Action 55 R&D Progress 55 SKL-16036 - Drug Profile 56 Product Description 56 Mechanism Of Action 56 R&D Progress 56 Small Molecule to Activate IL-10 for Bacterial Infections and Crohn's Disease - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 Synthetic Peptides to Inhibit IL-10 and IFN Gamma for Cancer, Viral Infections and Inflammatory Diseases - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 XT-101 - Drug Profile 59 Product Description 59 Mechanism Of Action 59 R&D Progress 59 XT-150 - Drug Profile 60 Product Description 60 Mechanism Of Action 60 R&D Progress 60 Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) - Dormant Projects 61 Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) - Discontinued Products 64 Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) - Featured News & Press Releases 65 Jun 06, 2016: ARMO BioSciences AM0010 Demonstrates Promising Clinical Data as an Immuno-oncology Monotherapy and in Combination with an Anti-PD-1 Checkpoint Inhibitor in Advanced Solid Tumors, Including Immune-Resistant Cancers 65 Apr 20, 2016: ARMO BioSciences Announces AM0010 Clinical Data to be Presented at the American Society of Clinical Oncology Annual Meeting in June 2016 66 Mar 31, 2016: Xalud Therapeutics Discovers Potential Solution for Opioid Abuse Crisis 67 Mar 16, 2016: ARMO BioSciences to Present New Clinical Trial Results for AM0010 at Upcoming Medical Conferences 68 Jan 08, 2016: ARMO BioSciences to Present at the 34th Annual J.P. Morgan HealthCare Conference 68 Oct 30, 2015: ARMO BioSciences Presents Positive Phase 1 Trial Results of AM0010 at Upcoming Medical Conferences 69 Oct 06, 2015: Biotest reaches the next milestone in the clinical development of its monoclonal antibody BT-063 by starting the clinical phase IIa trial in the indication systemic lupus erythematosus 69 Jun 01, 2015: ARMO BioSciences Announces Efficacy and Safety Data for Immuno-Oncology Program with Novel Mechanism of Action 70 May 13, 2015: ARMO BioSciences Announces Presentation on Promising Immuno-Oncology Program at 2015 ASCO Annual Meeting 71 Jun 23, 2014: Cytovance Biologics selected for GMP manufacture of AM0010 for ARMO BioSciences 71 Nov 25, 2013: ARMO BioSciences Initiates Phase 1 Clinical Trial of First-In-Class Cancer Immunotherapy 72 Apr 11, 2012: University Of Leuven And ActoGeniX Announce Study Results Of ActoBiotic In Treatment Of Type 1 Diabetes 72 Sep 30, 2009: Biotest AG Announces Initiation of Clinical development of BT-063 73 Appendix 74 Methodology 74 Coverage 74 Secondary Research 74 Primary Research 74 Expert Panel Validation 74 Contact Us 74 Disclaimer 75

List of Tables Number of Products under Development for, H1 2016 9 Number of Products under Development by Therapy Area, H1 2016 10 Number of Products under Development by Indication, H1 2016 11 Comparative Analysis by Late Stage Development, H1 2016 13 Comparative Analysis by Early Stage Products, H1 2016 14 Number of Products under Development by Companies, H1 2016 15 Products under Development by Companies, H1 2016 16 Products under Development by Companies, H1 2016 (Contd..1) 17 Number of Products under Investigation by Universities/Institutes, H1 2016 18 Products under Investigation by Universities/Institutes, H1 2016 19 Assessment by Monotherapy/Combination Products, H1 2016 20 Number of Products by Stage and Mechanism of Action, H1 2016 22 Number of Products by Stage and Route of Administration, H1 2016 24 Number of Products by Stage and Molecule Type, H1 2016 26 Pipeline by BioMAS Ltd., H1 2016 27 Pipeline by Biotest AG, H1 2016 28 Pipeline by enGene, Inc, H1 2016 29 Pipeline by Intrexon Corporation, H1 2016 30 Pipeline by LEO Pharma A/S, H1 2016 31 Pipeline by Merck & Co., Inc., H1 2016 32 Pipeline by P2D Bioscience, H1 2016 33 Pipeline by Pfizer Inc., H1 2016 34 Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2016 35 Dormant Projects, H1 2016 61 Dormant Projects (Contd..1), H1 2016 62 Dormant Projects (Contd..2), H1 2016 63 Discontinued Products, H1 2016 64 List of Figures Number of Products under Development for, H1 2016 9 Number of Products under Development by Therapy Area, H1 2016 10 Number of Products under Development by Top 10 Indication, H1 2016 11 Comparative Analysis by Early Stage Products, H1 2016 14 Assessment by Monotherapy/Combination Products, H1 2016 20 Number of Products by Mechanism of Actions, H1 2016 21 Number of Products by Stage and Mechanism of Actions, H1 2016 21 Number of Products by Routes of Administration, H1 2016 23 Number of Products by Stage and Routes of Administration, H1 2016 23 Number of Products by Molecule Types, H1 2016 25 Number of Products by Stage and Molecule Type, H1 2016 25

BioMAS Ltd. Biotest AG enGene, Inc Intrexon Corporation LEO Pharma A/S Merck & Co., Inc. P2D Bioscience Pfizer Inc. SK Biopharmaceuticals Co., Ltd.